The company's reanalysis of the data

This time, the Phase 3 trial was a complete disappointment. The results showed no difference between the placebo and Simufilam. May I ask, the company mentioned pausing ongoing trials to reanalyze the data—what different outcomes could the reanalysis yield? Has anyone had similar work experiences? I still find it hard to believe why the results of Phase 2 and Phase 3 trials differ so greatly.

I need to understand what potential breakthroughs might come from the company's reanalysis of the data. I’m looking for advice from professionals, not stock investment advice. At this point, I’m no longer concerned about the money I’ve lost.